G1 Therapeutics to Present Data on Trilaciclib at North America Conference on Lung Cancer (NACLC)GlobeNewsWire • 10/15/20
G1 Therapeutics to Present Data on Oral CDK4/6 Inhibitor Lerociclib at European Society for Medical Oncology (ESMO) Virtual 2020 CongressGlobeNewsWire • 09/14/20
G1 Therapeutics to Participate in Four Investor Conferences in September 2020GlobeNewsWire • 09/02/20
G1 Therapeutics Announces Acceptance and Priority Review of NDA for Trilaciclib for Patients with Small Cell Lung CancerGlobeNewsWire • 08/17/20
G1 Therapeutics' (GTHX) CEO Mark Velleca on Q2 2020 Results - Earnings Call TranscriptSeeking Alpha • 08/06/20
G1 Therapeutics to Participate in BTIG and Wedbush Healthcare Conferences in August 2020GlobeNewsWire • 08/04/20
G1 Therapeutics to Provide Second Quarter 2020 Corporate and Financial Update on August 5, 2020GlobeNewsWire • 07/29/20
G1 Therapeutics and Boehringer Ingelheim Announce Co-Promotion Agreement for Trilaciclib in Small Cell Lung Cancer in the United States and Puerto RicoGlobeNewsWire • 06/30/20
G1 Therapeutics and Genor Biopharma Announce Exclusive License Agreement for Lerociclib in Asia-Pacific RegionGlobeNewsWire • 06/22/20
G1 Therapeutics Announces Flexible Credit Financing for Up to $100 Million with Hercules CapitalGlobeNewsWire • 06/01/20
G1 Therapeutics, Inc. (GTHX) CEO Mark Velleca on Q1 2020 Results - Earnings Call TranscriptSeeking Alpha • 05/10/20
G1 Therapeutics Announces Appointment of New Board Member and Chief Commercial OfficerGlobeNewsWire • 03/12/20
G1 Therapeutics, Inc. (GTHX) CEO Mark Velleca on Q4 2019 Results - Earnings Call TranscriptSeeking Alpha • 02/27/20
G1 Therapeutics to Participate in Guggenheim Health Talks: Oncology Day on February 13, 2020GlobeNewsWire • 02/06/20
Quantum Leap Healthcare Collaborative and G1 Therapeutics Announce the Selection of Trilaciclib in the I-SPY 2 TRIAL for Breast CancerGlobeNewsWire • 01/14/20